Safety and continuity of second‑ and third‑line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer

Kimura,Michio; Usami,Eiseki; Kanematsu,Tetsufumi; Iwai,Mina; Yoshimura,Tomoaki; Mori,Hiromi; Sugiyama,Tadashi; Teramachi,Hitomi

doi:10.3892/mco.2014.260

Safety and continuity of second‑ and third‑line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer

Authors:
- Michio Kimura
- Eiseki Usami
- Tetsufumi Kanematsu
- Mina Iwai
- Tomoaki Yoshimura
- Hiromi Mori
- Tadashi Sugiyama
- Hitomi Teramachi
View Affiliations

Affiliations: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503‑8502, Japan, Department of Pharmacy, Gifu Social Insurance Hospital, Kani, Gifu 509-0206, Japan, Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Gifu 501‑1196, Japan, Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Gifu 501‑1196, Japan
Published online on: February 14, 2014 https://doi.org/10.3892/mco.2014.260
Pages: 466-472

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the treatment of advanced or recurrent gastric cancer, the prolongation of survival depends on the use of second‑line therapy, with paclitaxel (PTX) or irinotecan (CPT‑11) as the key agents. The present study aimed to retrospectively investigate the safety and continuity of weekly PTX and CPT‑11 monotherapy as second‑ or third‑line treatment for advanced or recurrent gastric cancer. A total of 62 patients who had received PTX or CPT‑11 for gastric cancer at the Ogaki Municipal Hospital (Ogaki, Japan) were retrospectively reviewed. Of the 47 patients who received PTX as second‑line therapy, 13 (27.7%) received third‑line therapy with CPT‑11. Second‑line PTX and third‑line CPT‑11 were discontinued due to progressive disease (PD) in 27 and 7 cases, respectively, and deterioration in the performance status (PS) in 20 and 4 cases, respectively. Only 1 case of discontinuation due to adverse events (AEs) was reported for third‑line CPT‑11. Furthermore, of the 15 patients who received CPT‑11 as second‑line treatment, 11 (73.3%) then received PTX as third‑line treatment. Second‑line CPT‑11 and third‑line PTX were discontinued due to PD in 9 and 6 cases, respectively, and deterioration in the PS in 4 and 5 cases, respectively, whereas there was only 1 case of discontinuation due to AEs for second‑line CPT‑11. Severe AEs for PTX and CPT‑11 were infrequent; however, the frequency of diarrhea was high when PTX was administered as third‑line therapy (63.6%), whereas the frequency of malaise was high when CPT‑11 was administered as second‑ (73.3%) and third‑line (76.9%) therapy. In conclusion, severe AEs due to PTX and CPT‑11 as second‑ and third‑line treatment for advanced or recurrent gastric cancer are infrequent and patients are generally able to continue treatment. However, the possibility of diarrhea with third‑line PTX and malaise with second‑ and third‑line CPT‑11 treatment should be considered when planning chemotherapy.

View Figures

View References

1.	Boku N, Yamamoto S, Fukuda H, et al Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Shitara K, Oze I, Mizota A, et al: Randomized phase II study comparing dose escalated weekly paclitaxel vs. standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer. Jpn J Clin Oncol. 41:287–290. 2011. View Article : Google Scholar
4.	Shimoyama R, Yasui H, Boku N, et al: Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer. 12:206–211. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T and Onozawa Y: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 9:14–18. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Egawa T, Kubota T, Nagashima A, Doi M, Kitano M, Hayashi S, Yoshii H, Saikawa Y and Kitajima M: Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer. Jpn J Canc Chemother. 31:877–881. 2004.(In Japanese).
7.	Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, Tanabe S, Higuchi K, Sasaki T and Sekikawa T; Tokyo Cooperative Oncology Group (TCOG GI Group): Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 trial. Jpn J Clin Oncol. 39:713–719. 2009.
8.	Matsuda G, Kunisaki C, Makino H, et al: Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer. Anticancer Res. 29:2863–2867. 2009.PubMed/NCBI
9.	Kodera Y, Ito S, Mchizuki Y, et al Chubu Clinical Cancer Group: A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 27:2667–2671. 2007.PubMed/NCBI
10.	Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW and Bae JM: Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol. 34:8–13. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Kawamura H, Yokota R, Watarai H, et al: Third-line CPT-11 chemotheraphy for gastric cancer cases of non-curative gastrectomy or recurrence. Jpn J Canc Chemother. 37:1051–1054. 2010.(In Japanese).
12.	Kuculzeybek Y, Dirican A, Erten C, Somali I, Can A, Demir L, Bayoglu IV, Akyol M, Medeni M and Tarhan MO: Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. Asian Pac J Cancer Prev. 13:2771–2774. 2012. View Article : Google Scholar : PubMed/NCBI
13.	Oda H, Mizuno T, Yamashita Y, Nomura H, Saito K, Tamaru S, Kageyama S and Katayama N: Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report. Jpn J Canc Chemother. 38:1517–1520. 2011.(In Japanese).
14.	Goto A, Sukawa Y, Igarashi H, et al: Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy. Jpn J Canc Chemother. 38:1461–1466. 2011.(In Japanese).
15.	Farhat FS: A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol. 24:137–146. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Fujitani K, Narahara H, Takiuchi H, Tsujinaka T, Satomi E, Gotoh M, Hirao M, Furukawa H and Taguchi T: Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology. 69:414–420. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Kumagai K, Saikawa Y, Nakamura R, Takahashi T, Kubota T, Kumai K, Kitagawa Y and Kitajima M: Clinical experience of second-line chemotherapy with S-1/CPT-11 for highly advanced gastric cancer. Jpn J Canc Chemother. 35:245–250. 2008.(In Japanese).
18.	Komatsu Y, Yuki S, Fuse N, et al: Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. Adv Ther. 27:483–492. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Shitara K, Matsuo K, Mizota A, et al: Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. Gastric Cancer. 14:155–160. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G and Reichardt P: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 47:2306–2314. 2011. View Article : Google Scholar
21.	Kang JH, Lee SI, Lim do H, et al: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
22.	Akasaka O, Iwase S, Miwa H, Ando T, Morita S, Koh R, Kasama M, Matsueda R and Anan H: Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer. Jpn J Canc Chemother. 36:1833–1837. 2009.(In Japanese).
23.	Kimura M, Usami E, Okada K, Nakao T, Yoshimura T and Yasuda T: Safety evaluation for chemotherapy with S-1 and cisplatin based on nutrition factors using body mass index and serum albumin levels in patients with advanced and recurrent gastric cancer. J Jpn Soc Hosp Pharm. 45:785–788. 2009.(In Japanese).
24.	Kimura M, Morihata K, Ito D, Iwai M, Okada K, Usami E, Nakao T, Yoshimura T and Yasuda T: Continuous administration and safety of S-1 in adjuvant chemotherapy for gastric cancer. Jpn J Canc Chemother. 37:829–834. 2010.(In Japanese).
25.	Ueda S, Hironaka S, Yasui H, et al: Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. J Clin Oncol. 30:(American Society of Clinical Oncology, 48th Annual Meeting): abs. 4002. 2012.
26.	Shitara K, Matsuo K, Takahari D, et al: Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann Oncol. 21:2403–2409. 2010. View Article : Google Scholar : PubMed/NCBI